Uceris* — Medicare Part D Spending

Generic: Budesonide | Manufacturer: Overall

2023 Spending

$1.9M

2023 Claims

1,324

2023 Beneficiaries

577

Cost/Unit (2023)

$26.84

5-Year Spending Trend (2019-2023)

Year	Total Spending	Claims	Beneficiaries	Cost/Unit
2019	$6.4M	4,172	1,562	$36.53
2020	$4.8M	3,390	1,204	$27.66
2021	$3.7M	2,600	1,092	$24.20
2022	$3.3M	2,368	951	$22.76
2023	$1.9M	1,324	577	$26.84

5Y CAGR (cost/unit): -7.4%YoY Change (2022-2023): 17.9%

📊

DrugPricePeek Editorial TeamData Specialists

The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.

✓ Sourced from CMS NADAC & Medicare Part D✓ Quarterly review✓ No paid placements

Read our full methodology or contact us with corrections.

Frequently Asked Questions

How much does Medicare spend on Uceris*?

In 2023, Medicare Part D spent $1.9M on Uceris* (Budesonide), serving 577 beneficiaries across 1,324 claims.

What is the cost per unit of Uceris* under Medicare?

The weighted average cost per dosage unit of Uceris* was $26.84 in 2023. The 5-year compound annual growth rate (2019-2023) was -7.4%.

Who manufactures Uceris*?

Uceris* (generic name: Budesonide) is manufactured by Overall. There are 2 manufacturer(s) listed in the CMS database for this drug.

Is Uceris* covered by Medicare Part D?

Yes, Uceris* is included in Medicare Part D spending data, indicating it is covered by Part D plans. However, specific coverage and tier placement vary by plan. Check with your specific Part D plan for formulary details.

Where does this Medicare spending data come from?

All Medicare Part D spending data comes from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Spending by Drug dataset, which is publicly available at data.cms.gov.

Explore More Data Tools

For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.